19 June 2013
Keywords: potential, new, use, rituximab, cll, world, biotechnology
Article | 13 October 2008
World biotechnology giant Genentech and USA-based Biogen Idec say that a global Phase III study of Rituxan (rituximab) with chemotherapy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 October 2008
18 June 2013
© 2013 thepharmaletter.com